Boston Scientific Balance Sheet Health
Financial Health criteria checks 5/6
Boston Scientific has a total shareholder equity of $20.6B and total debt of $10.6B, which brings its debt-to-equity ratio to 51.3%. Its total assets and total liabilities are $37.1B and $16.5B respectively. Boston Scientific's EBIT is $2.7B making its interest coverage ratio 10.7. It has cash and short-term investments of $2.9B.
Key information
51.3%
Debt to equity ratio
US$10.57b
Debt
| Interest coverage ratio | 10.7x |
| Cash | US$2.91b |
| Equity | US$20.61b |
| Total liabilities | US$16.50b |
| Total assets | US$37.11b |
Recent financial health updates
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10
Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Recent updates
Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($9.0B) exceed its short term liabilities ($5.6B).
Long Term Liabilities: BSX's short term assets ($9.0B) do not cover its long term liabilities ($10.9B).
Debt to Equity History and Analysis
Debt Level: BSX's net debt to equity ratio (37.1%) is considered satisfactory.
Reducing Debt: BSX's debt to equity ratio has reduced from 101.2% to 51.3% over the past 5 years.
Debt Coverage: BSX's debt is well covered by operating cash flow (24.9%).
Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (10.7x coverage).